最新研究顯示孕婦接種 RSV 疫苗效果顯著
New study shows maternal RSV vaccine is highly effective
來自英國衛生安全局的一項開創性新研究證實，母體呼吸道合胞病毒（RSV）疫苗對嬰兒健康有著重大影響。
A groundbreaking new study from the UK Health Security Agency has confirmed that the maternal RSV vaccine is a game-changer for infant health.
研究人員透過分析近30萬名嬰兒的數據發現，當母親在分娩前至少兩週接種疫苗，新生兒因感染RSV而需要住院治療的風險降低了81.3%。
By analyzing data from nearly 300,000 babies, researchers found that when mothers receive the vaccine at least two weeks before birth, the risk of their newborns requiring hospital care for RSV drops by 81.3%.
為達到最佳防護效果，在分娩前至少四週接種疫苗，保護效力可提升至近85%。
For optimal protection, administering the vaccine at least four weeks before delivery boosts effectiveness to nearly 85%.
疫苗的運作原理是誘發母親的免疫系統產生抗體，這些抗體隨後經由胎盤傳遞給胎兒，為嬰兒提供極為關鍵的被動免疫力。
The vaccine works by triggering the mother's immune system to create antibodies, which are then passed to the fetus via the placenta, granting the infant vital passive immunity.
這對面臨最高風險的早產兒來說，尤其具有救命的意義。
This is especially life-saving for preterm babies, who face the highest risks.
公共衛生專家強調，這些研究結果證實在妊娠第三三月期早期接種疫苗，以確保有足夠時間進行抗體轉移是至關重要的。
Public health experts emphasize that these findings validate vaccination as early as the third trimester to ensure enough time for antibody transfer.
由於RSV仍是導致幼兒罹患細支氣管炎等嚴重呼吸道疾病的主要原因，這項真實世界的證據證明了母體疫苗接種是一種高度成功的策略，有助於減少住院率，並確保我們最脆弱的新生兒在生命最關鍵的頭幾個月裡得到保護。
As RSV remains a leading cause of severe respiratory issues like bronchiolitis in young infants, this real-world evidence proves that maternal vaccination is a highly successful strategy for reducing hospitalizations and keeping our most vulnerable newborns safe during their critical first few months of life.
